公开(公告)号：US20200002310A1

公开(公告)日：2020-01-02

申请号：US16567675

申请日：2019-09-11

Applicant: Pfizer Inc.

Inventor： Michael Joseph Luzzio ,  Kevin Daniel Freeman-Cook ,  Samit Kumar Bhattacharya ,  Matthew Merrill Hayward ,  Catherine Angela Hulford ,  Christopher Lowell Autry ,  Xumiao Zhao ,  Jun Xiao ,  Kendra Louise Nelson

IPC: C07D401/12 ,  C07D239/48 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D241/20 ,  C07D475/00

Abstract: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

公开(公告)号：US20180044344A1

公开(公告)日：2018-02-15

申请号：US15664265

申请日：2017-07-31

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D401/14

CPC classification number: C07D487/04 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11718603B2

公开(公告)日：2023-08-08

申请号：US17235836

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)




and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20220324872A1

公开(公告)日：2022-10-13

申请号：US17841138

申请日：2022-06-15

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D471/04 ,  C07D401/14

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11203594B2

公开(公告)日：2021-12-21

申请号：US16849329

申请日：2020-04-15

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Douglas Carl Behenna ,  Kimberly O. Cameron ,  Ping Chen ,  John M. Curto ,  Kevin Daniel Freeman-Cook ,  Mehran Jalaie ,  Robert Steven Kania ,  Yajing Lian ,  Sajiv Krishnan Nair ,  Cynthia Louise Palmer ,  Martin Youngjin Pettersson ,  Eugene Yuanjin Rui ,  Matthew Sammons ,  Qingyi Yang ,  Liying Zhang

IPC: C07D471/04 ,  A61P9/12

Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

公开(公告)号：US20210269425A1

公开(公告)日：2021-09-02

申请号：US17235846

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20190135817A1

公开(公告)日：2019-05-09

申请号：US16251032

申请日：2019-01-17

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2 , R2A , R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US10233188B2

公开(公告)日：2019-03-19

申请号：US15664265

申请日：2017-07-31

Applicant: Pfizer Inc.

Inventor： Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic

IPC: A61K31/519 ,  A61K31/4375 ,  A61K31/4545 ,  C07D487/04 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20160130250A1

公开(公告)日：2016-05-12

申请号：US15000944

申请日：2016-01-19

Applicant: PFIZER, INC.

Inventor： Michael Joseph Luzzio ,  Kevin Daniel Freeman-Cook ,  Samit Kumar Bhattacharya ,  Matthew Merrill Hayward ,  Catherine Angela Hulford ,  Christopher Lowell Autry ,  Xumiao Zhao ,  Jun Xiao ,  Kendra Louise Nelson

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07D239/48 ,  C07D241/20 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D475/00

Abstract: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.